Search

Your search keyword '"Visseren FLJ"' showing total 3,908 results

Search Constraints

Start Over You searched for: "Visseren FLJ" Remove constraint "Visseren FLJ"
3,908 results on '"Visseren FLJ"'

Search Results

1. Lifetime and 10-year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE-T1D model.

2. Dietary habits and compliance with dietary guidelines in patients with established cardiovascular disease.

3. Risk Stratification in Patients with Ischemic Stroke and Residual Cardiovascular Risk with Current Secondary Prevention

4. Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study.

5. Arterial calcification volume is associated with a higher risk of cardiovascular events in pseudoxanthoma elasticum.

6. Vitamin D status, physical activity and long-term mortality risk after myocardial infarction: a prospective analysis in the Alpha Omega Cohort.

7. Prediction of Severe Baseline Asymptomatic Carotid Stenosis and Subsequent Risk of Stroke and Cardiovascular Disease.

8. Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions.

9. Development and validation of a lifetime prediction model for incident type 2 diabetes in patients with established cardiovascular disease: the CVD2DM model.

10. Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.

11. Impact of the VTE-PREDICT calculator on clinicians' decision making in fictional patients with venous thromboembolism: a randomized controlled trial.

12. Cost-effectiveness of Mediterranean diet and physical activity in secondary cardiovascular disease prevention: results from the UCC-SMART cohort study.

13. Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 randomized controlled trials.

14. Estimating uncertainty when providing individual cardiovascular risk predictions: a Bayesian survival analysis.

15. Personalized lifetime prediction of survival and treatment benefit in patients with heart failure with reduced ejection fraction: The LIFE-HF model.

16. Variability in benefit from intensive insulin therapy on cardiovascular events in individuals with type 1 diabetes: A post hoc analysis of the DCCT/EDIC study.

17. Adding ethnicity to cardiovascular risk prediction: External validation and model updating of SCORE2 using data from the HELIUS population cohort.

18. Cyclical Etidronate Reduces the Progression of Arterial Calcifications in Patients with Pseudoxanthoma Elasticum: A 6-Year Prospective Observational Study.

20. Effect of Pemafibrate on Diabetic Foot Ulceration and Gangrene: An Exploratory Analysis From PROMINENT.

21. Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias-A report from the European Society of Cardiology Cardiovascular Round Table.

22. Relationship of neutrophil-to-lymphocyte ratio, in addition to C-reactive protein, with cardiovascular events in patients with type 2 diabetes.

23. Sex differences in modifiable risk factors for stroke incidence and recurrence: the UCC-SMART study.

24. Association of body mass index and waist circumference with long-term mortality risk in 10,370 coronary patients and potential modification by lifestyle and health determinants.

25. Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis.

26. Impact of the 2021 European Society for Cardiology prevention guideline's stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease.

27. Prevalence and determinants of self-reported low-fat-, low-salt-, and vegetarian diets in patients with cardiovascular disease between 1996 and 2019.

28. Generalisability of trials on antithrombotic treatment intensification in patients with cardiovascular disease.

29. Diet in secondary prevention: the effect of dietary patterns on cardiovascular risk factors in patients with cardiovascular disease: a systematic review and network meta-analysis.

30. Validation of Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons in the EPIC-Norfolk prospective population cohort.

31. Long-term lifestyle change and risk of mortality and Type 2 diabetes in patients with cardiovascular disease.

32. Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease.

33. Plasma lipids in Pseudoxanthoma Elasticum (PXE) patients: A comparative study with population-based reference values and Non-PXE controls.

34. Validation of spot urine in estimating 24-h urinary sodium, potassium and sodium-to-potassium ratio during three different sodium diets in healthy adults.

35. Comparison of the European and US guidelines for lipid-lowering therapy in primary prevention of cardiovascular disease.

37. The relevance of competing risk adjustment in cardiovascular risk prediction models for clinical practice.

38. Validating the SMART2 Score in a Racially Diverse High-Risk Nationwide Cohort of Patients Receiving Coronary Artery Bypass Grafting.

39. LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis.

40. Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2.

41. Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.

42. Intima-media thickness at the near or far wall of the common carotid artery in cardiovascular risk assessment.

43. Composition and distribution of lipoproteins after evolocumab in familial dysbetalipoproteinemia: A randomized controlled trial.

44. Effect of adipose tissue quantity and dysfunction on the risk of cancer in individuals with and without type 2 diabetes.

45. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

48. ESC 2021 Guideline on the prevention of cardiovascular disease in clinical practice clinical practice

49. Number of measurement days needed for obtaining a reliable estimate of home blood pressure and hypertension status

50. C-Reactive Protein and Risk of Incident Heart Failure in Patients With Cardiovascular Disease.

Catalog

Books, media, physical & digital resources